+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Middle East & Africa Ovarian Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 70 Pages
  • August 2020
  • Region: Africa, Middle East
  • Mordor Intelligence
  • ID: 5174965
The major factors that are responsible for the growth of the market includes growing burden of ovarian cancer and use of combination therapies for the treatment of ovarian cancer. The incidences of ovarian cancer are high in women aged 55-64 years. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty in eating, and urinary symptoms. According to Globocan, in 2018, there were around 1,371 new ovarian cancer cases in South Africa and around 971 people died due to this disease. However, the others factors, such as lack of awareness in emerging and low income economies are expected to impede the market growth.

Key Market Trends

CT Scan Segment is Expected to Show Better Growth in the Forecast Period

Computed Tomography (CT) is an imaging procedure that uses special X-ray equipment to create detailed pictures, or scans, of areas inside the body. It is also called computerized tomography and computerized axial tomography (CAT). This equipment does not show small ovarian tumors well, but they can see larger tumors, and may be able to see if the tumor is growing into nearby structures. It can also find the enlarged lymph nodes, signs of cancer spread to the liver or other organs, or signs that an ovarian tumor is affecting the kidneys or bladder. Furthermore, with the rising burden of ovarian cancer and technological advancements is expected to fuel the market growth over the forecast period.

Competitive Landscape

The majority of ovarian cancer diagnostics and therapeutics products is being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. This has helped the market grow.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Ovarian Cancer
4.2.2 Use of Combination Therapies for the Treatment of Ovarian Cancer
4.3 Market Restraints
4.3.1 Lack of Awareness in Emerging and Low Income Economies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Cancer Type
5.1.1 Epithelial Ovarian Tumors
5.1.2 Ovarian Germ Cell Tumors
5.1.3 Others
5.2 By Modality
5.2.1 Diagnosis Biopsy Blood Tests Ultrasound PET CT Scan Other Diagnosis
5.2.2 Therapeutics Chemotherapy Radiation Therapy Immunotherapy Hormonal Therapy Others
5.3 Geography
5.3.1 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
6.1 Company Profiles
6.1.1 Astrazeneca plc
6.1.2 Bristol Myers Squibb Company
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffman-La Roche Ltd
6.1.5 Glaxosmithkline Plc
6.1.6 Johnson and Johnson (Janssen Pharmaceuticals)
6.1.7 Pfizer Inc.
6.1.8 Siemens Healthineers AG

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Astrazeneca plc
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffman-La Roche Ltd
  • Glaxosmithkline Plc
  • Johnson and Johnson (Janssen Pharmaceuticals)
  • Pfizer Inc.
  • Siemens Healthineers AG